Hot Pharma Stocks / Ideen / Blockbuster

    Hot Pharma Stocks / Ideen / Blockbuster

    yihi wrote:

    Quote
    So ist es. Dieses Medikament ist wahrscheinlich wirkungslos. Ob man auf einen Rebound setzen sollte?


    habe schlechte erfahrungen mit rebound gemacht.

    wer weiss......

    Hot Pharma Stocks / Ideen / Blockbuster

    Wie ich schon letzte Woche geschrieben habe, war ich euphorisch.

    Das hat dazu geführt, das ich das Risiko/Gewinn Verhältnis nicht abgewogen habe. Ich zahle jetzt die Straffe für mein Handeln. Heute bei Börsen eröffnung werde ich meine Positionen, CORT, CYTK und CAPS schliessen.

    Auch die SNSS Posi.

    Hot Pharma Stocks / Ideen / Blockbuster

    Vagnum wrote:

    Quote
    Wie ich schon letzte Woche geschrieben habe, war ich euphorisch.

    Das hat dazu geführt, das ich das Risiko/Gewinn Verhältnis nicht abgewogen habe. Ich zahle jetzt die Straffe für mein Handeln. Heute bei Börsen eröffnung werde ich meine Positionen, CORT, CYTK und CAPS schliessen.

    Auch die SNSS Posi.


    he alter.. fertig biotech? völliger CAPS schock?


    *Vagnumtröst*

    INHX

    etwas älter:


    Investors over at Inhibitex Inc.(NASDAQ: INHX) are still anxiously awaiting results from their Phase 2 trial using FV-100 for the treatment of shingles. Investors should know that the trial is evaluating FV-100 against an active control arm in Glaxo’s Valtrex. VALTREX® had total U.S. sales of about $500 million(for the shingles indication). FV-100 has the potential to offer several advantages over existing treatments. FV-100 uses once-daily dosing, as opposed to multiple doses daily for for other treatments(Valtrex, acyclovir & famciclovir). The primary endpoint is a reduction in herpes zoster associated pain and severity as measured by the Zoster Burden of Illness (ZBOI) scale after 30 days. Based on preclinical data, FV-100 has been shown to have significantly faster onset of antiviral activity than currently options, at much lower dosing levels. The trial is testing whether Inhibitex’s FV-100 can reduce the incidence, severity, and duration of shingles-related symptoms, including lesions, acute pain, and post herpetic neuralgia (PHN) relative to Valtrex.


    With the potential to have no signs of renal impairment(a potential side effect from Valtrex), better dosing schedule and reduction in PHN, FV-100 could easily become the new standard of care for the treatment of shingles. And according to Zack's analyst, Jason Napodano, "Therefore, even if the phase II data above only proves that FV-100 is on-par in terms of efficacy to Valtrex, Inhibitex has a significant market opportunity by offering once-daily dosing and improved safety performance in patients with renal insufficiency." INHX has made it clear that they want to partner this drug and positive data should certainly attract potential suitors.


    dann kam:


    Inhibitex Reports Promising Top-Line Results from Phase II Trial of FV-100 for the Treatment of Shingles


    “We believe the tolerability profile and treatment advantages observed across the various pain endpoints in this proof-of-concept study confirm FV-100’s potential as a standard of care therapy for the treatment of shingles”


    http://www.businesswire.com/ne…Top-Line-Results-Phase-II

    Hot Pharma Stocks / Ideen / Blockbuster

    yihi


    Bis Ende Jahr bekommst Du das Abo für $295. Ab 2011 kostet es dann $497.


    Some of the features of the new BioRunUp.com include:


    - Detailed Reports on Upcoming FDA / Clinical Trades - Live Chat Room *NEW*

    - Video Lessons / Trade Reviews *NEW*

    - BioRunUp Forums - A community of informed traders

    - Analyst Reports with consistently updated summaries (Sample)

    - Run-Up Valuation Studies (Sample)

    - Weekly Newsletter

    - Email / SMS (Text Message) Alerts of critical news (Sample)

    - A New Clinical Calendar (Sample)

    - Screenshots of BioRunUp and mikehavRx's Trading Accounts

    - Merger with mikehavRx.com to offer combined service

    - A More Detailed FDA Calendar, linked to PDF reports

    - Historical FDA Tracker

    - BioRunUp Live Newsfeed

    - Spreadsheet download for clinical / regulatory catalyst calendar plus integrated Google Docs / Finance tracking

    - Mike Havrilla's portfolio and stock watch list along with Profit.ly stock trades and performance stats

    - Corporate Event Google Calendar tracking for bio-catalyst stocks

    - Bio-Pharma, FDA, Clinical Trials, and Stock Market News Updates

    - HavRx Healthcare Sub-Sector Indexes

    - Increased Organization of Tracking Upcoming Catalysts

    - A Growing Focus on Upcoming Clinical Trial Catalysts

    - Direct Email Communication


    http://www.biorunup.com/affiliates?refer=20101119_1